Reported 12 months ago
Longen, aiming for the potential business opportunities after the passage of the 'Regenerative Medicine Dual Law' on July 1, 2024, continues to provide CDMO services and collaborate with 19 medical institutions in addition to approved autologous cell therapy technologies such as ADCV, CIK, and Gamma Delta-T. They have also actively invested in allogeneic cell therapy, with a strong focus on critical illnesses. With a significant increase in monthly and half-yearly performance, Longen's total revenue in June was NT$62.12 million, a year-on-year growth of 8.4%, and NT$342 million in the first half of the year, a 23% annual increase.
Source: YAHOO